Faculty, Staff and Student Publications

Language

English

Publication Date

12-1-2025

Journal

Advanced Science

DOI

10.1002/advs.202507718

PMID

41042068

PMCID

PMC12697795

PubMedCentral® Posted Date

10-3-2025

PubMedCentral® Full Text Version

Post-print

Abstract

Poor clinical responses to immune checkpoint blockade (ICB) observed in ovarian cancer (OC) highlight an unmet need to understand the mechanisms driving immune evasion in this disease. To address this, an integrative analysis is conducted by combining in vitro genome‐wide immune screens, in vivo ICB screens, and clinical data mining, and METTL5 is identified as a crucial OC‐intrinsic factor that promotes immune resistance. Immunologically “cold” OC tumors and poor responders to ICB exhibit elevated METTL5 expression. Mechanistically, knocking out (KO) METTL5 in OC disrupts ATF4 translation by altering 18S rRNA m6A levels, leading to the downregulation of SLC7A11 and SLC3A2, whose function is to suppress ferroptosis activity. Consequently, METTL5 KO enhances tumor sensitivity to T cell‐mediated antitumor immunity. Notably, the immune‐sensitive phenotypes seen in METTL5‐KO tumors can be reversed by either ATF4 overexpression or ferroptosis inhibition. These findings underscore the central role of the METTL5/ATF4/ferroptosis axis in controlling OC responses to immunotherapy.

Keywords

Ferroptosis, Activating Transcription Factor 4, Female, Humans, Ovarian Neoplasms, Methyltransferases, Animals, Mice, T-Lymphocytes, Cell Line, Tumor, Gene Expression Regulation, Neoplastic, ATF4, CRISPR screen, ferroptosis, immunotherapy, METTL5, ovarian cancer

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.